• Hustle Hub Stocks
  • Posts
  • Regeneron Pharmaceuticals, Inc DCF Stock Analysis. Buy or Sell?

Regeneron Pharmaceuticals, Inc DCF Stock Analysis. Buy or Sell?

Regeneron Pharmaceuticals, Inc DCF Stock Analysis.

In partnership with

Home insurance rates up by 76% in some states

Over the last 6 years, home insurance rates have increased by up to 76% in some states. Between inflation, costlier repairs, and extreme weather, premiums are climbing fast – but that doesn’t mean you have to overpay. Many homeowners are saving hundreds a year by switching providers. Check out Money’s home insurance tool to compare companies and see if you can save.

Regeneron Pharmaceuticals, Inc DCF Stock Analysis.

Here’s my assumptions:

Risk Free Rate (10 Years Interest Rate Swap): 3.391%

Risk Premium (Taken from the Aswath Damodaran equity premium spreadsheet): 4.33%

Interest Rate Spread on The Risk free rate ( For the cost of debt calculation): 3%

Historical Data

Revenue growth in the last 10 years (CAGR): 13.22%

Earnings growth in the last 10 years (CAGR): 21.37%

Unlevered Free Cash Flow growth in the last 10 years (CAGR): 39.34%

Future Assumptions

End of Year FCF growth: 10%

Growth until end of 2026: 20%

Growth until end of 2034: 10%

Perpetual growth: 3%

Net Debt: 16.024B

Outstanding Stock Options Present Value Assumption: $0.804B

Restricted Stock Units Present Value Assumption: $1.630B

Stock Valuation based on these assumptions: $1320

Last update 11/08/2025

All the content in this newsletter should be taken as informational content only. THIS IS NOT FINANCIAL ADVICE! Do your own Due Diligence before investing or contact a professional financial advisor.

I don’t have a position in Regeneron Pharmaceuticals, Inc (REGN) and I don’t plan to add a position in the coming days.